Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

Valle, Juan W; Dangoor, Adam; Beech, Janette; Sherlock, David; Lee, Siow Ming; Scarffe, J. H.; Swindell, Ric; Ranson, Malcolm R

doi:10.1038/sj.bjc.6602394

Cited by 24 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Median overall survival was 9 mo and was shorter than that in the study by Schmidinger et al [9] , but longer than that in previous PLD studies [8,10,19,21] . Among 18 responder/SD patients, nine (50%) were alive at 12 mo, while at the same time, none of those with PD was alive (P < 0.05).…”

Section: Discussioncontrasting

confidence: 44%

See 1 more Smart Citation

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Lorenzo¹,

Rea²,

Carlomagno³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase Ⅱ study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA). METHODS:Thirty-one patients with hystologicallyconfirmed, inoperable HCC, received combination c h e m o t h e ra p y w i t h P L D 2 5 m g / m q o n d 1 , 5 F U 1200 mg/mq in 48 h continuous infusion, and oral FA 30 mg on d 1 and 2 every 3 wk until disease progression or intolerable toxicity. RESULTS:The median age was 65 years (range 41-82) and 28 patients were hepatitis C virus seropositive (90%). The majority of patients were Child-Pugh Class B (55%). Two patients showed a partial response (PR), and 16 had stable disease (SD). With a median follow-up of 14 mo, the median time to progression of all evaluable patients was 4 mo (95% CI 1.7-7). Median overall survival was 9 mo (95% CI 3-24 mo). After 1 year, 9 of 18 PR/SD patients were alive. Chemotherapy was well tolerated.

show abstract

Section: Discussioncontrasting

confidence: 44%

“…Median time to progression was 4 mo, which is longer than that in other PLD studies, such as those by Valle et al and Halm et al [19,21] . Median overall survival was 9 mo and was shorter than that in the study by Schmidinger et al [9] , but longer than that in previous PLD studies [8,10,19,21] .…”

Section: Discussionmentioning

confidence: 56%

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Lorenzo¹,

Rea²,

Carlomagno³

et al. 2007

WJG

View full text Add to dashboard Cite

show abstract

“…The major difference is, while only one tumor in the previous study was HCC, we enrolled only HCC, which might have a different response to hyperthermia and PLD. HCC has a poorer response to PLD than other tumors, which might explain the results in this study [18,19]. Another difference was that the tumors in this study were small, so that RFA might destroy them completely.…”

Section: Discussioncontrasting

confidence: 43%

Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin

et al. 2010

View full text Add to dashboard Cite

Purpose Synergy between radiofrequency ablation (RFA) and chemotherapy was demonstrated for liver malignancy. We assess the efficacy of intravenous pegylated liposomal doxorubicin (PLD) for RFA in patients with small hepatocellular carcinoma (HCC). Methods This study was designed as a non-randomized control trial. Patients received either PLD (20 mg) intravenously before RFA, or standard RFA alone. Computed tomography was performed immediately and 4 weeks after RFA to obtain ablative diameter, area and volume for each tumor. The changes in ablation size were analyzed by paired images for each tumor. All patients were followed up regularly. Results A total of 24 patients with 29 HCCs, including 12 patients with 16 tumors (mean 2.2 cm ± 0.9) in the PLD and RFA group, and 12 patients with 13 tumors (2.4 cm ± 0.5) in the RFA alone group, were enrolled. The ablative diameter, area and volume significantly decreased 4 weeks after RFA. The ablative volume decrease was significantly greater for the RFA alone group than for the combination group (26.1 vs. 12.1%, p = 0.018). The 3-year cumulative tumor progression and survival rates did not differ significantly between the two groups. Conclusion Intravenous PLD before RFA reduced contraction of ablative volume and might have no impact on tumor progression and survival in patients with small HCC after RFA.

show abstract

“…The efficacy of PLD was evaluated in several phase II trials in patients with advanced HCC. Although a favorable toxicity profile has been observed, the studies failed to show meaningful clinical outcome (24)(25)(26)(27). The reduced uptake of PLD in organs including liver may be responsible for the lack of efficacy.…”

Section: Introductionmentioning

confidence: 99%

Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy

Kim

Talati

Kim

2017

J. Gastrointest. Oncol.

260

168

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor prognosis.The incidence of HCC and HCC-related deaths have increased over the last several decades. However, the treatment options for advanced HCC are very limited. Sorafenib remains the only drug approved for systemic treatment for advanced HCC. However, prior to sorafenib era conventional cytotoxic chemotherapies have been studied in advanced HCC. In this review, clinical studies of systemic chemotherapy for advanced HCC will be summarized and discussed.

show abstract

Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study

Cited by 24 publications

References 16 publications

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Radiofrequency ablation of small hepatocellular carcinoma with intravenous pegylated liposomal doxorubicin

Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy

Contact Info

Product

Resources

About